|
|
|
|
 |
Development Strategies
Growth Strategy
Æterna Zentaris is an integrated biopharmaceutical company with a core strategic area of competence in the development of pharmaceutical products. Æterna Zentaris sees itself on its way to achieving a leading position in research, development and manufacture of innovative therapeutics, especially in the fields of oncology and endocrinology.
These activities are supported by an international network of scientific collaborators as well as the in-house drug discovery unit which is mainly responsible for the research and development of novel active substances. This enables the Company to present the entire value-added chain from identification and provision of development candidates via research and development of active substances up to the development of marketable products, and to generate short-, medium- and long-term income on the basis of its own active substances.
Being an integrated biopharmaceutical company, Æterna Zentaris combines all areas which are necessary in the long term to develop innovative forms of therapy, and thus it possesses the expert knowledge required to develop a drug up to market maturity. This research competence at all development phases enables the Company to decide, on the basis of cost/benefit analyses, whether an active substance should be developed up to market maturity or whether it should be licensed out for selected territories or indications to a third party at an earlier stage.
The Company has now a deeply layered portfolio of active substances and product candidates in different phases of development and endeavors to further expand and develop this portfolio.
Partnering Strategy
As exemplified by our high quality network of collaborators, Æterna Zentaris is always looking for partners that will commit themselves to develop and distribute our compounds upon market approval by regulatory authorities. The usual business terms are composed of milestones, coverage of development cost and royalties on sales.
M&A
As part of our M&A strategy, Æterna Zentaris is always looking for new compounds that will have reached the latest development stage possible in our core therapeutic areas.
We are also looking on an ongoing basis for activities and discussions that could lead to the purchase of a company that would fall in the following strategic acquisition criteria:
- excellent scientific rationale;
- late-stage development;
- well-patented technology;
- strong management team;
- healthy financial position and
- existing partnership.
To enquire about partnering opportunities (in- or out-licensing), please contact our business development group:
Chantal Gravel
Director, Business Operations
Phone: (418) 652-8525
cgravel@aezsinc.com
|
 |
|
|
 |
